Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas

Bosnian Journal of Basic Medical Sciences

Volumn 10, Issue 3, 2010, Pages 192-196

  Legan, Mateja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cyclooxygenase 2; Gallbladder carcinoma; Glucose transporter i; Ps3

Indexed keywords

EID: 77957114369     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2010.2684     Document Type: Article

References (33)

1. Rückert J.C.R., Rückert R.L., Gellert K., Hecker K., Muller J.M. Surgery for carcinoma of the gallbladder. Hepato-Gastroenterol. 1996; 43: 527-533.
2. Kanoh K., Shimura T., Tsutsumi S., et al. Significance of contracted cholecystitis lessions as high risk for gallbladder carcinogenesis. Cancer Lett. 2001; 169: 7-14.
3. Tsuchida A., Itoi T., Aoki T., Koyanagi Y. Carcinogenetic process in gallbladder mucoa with pancreaticobiliary maljunction (review). Oncol. Rep. 2003; 10:1693-1699
4. Sasatomi E., Tokunaga O., Miyazaki K. Precancerous conditions of gallbladder carcinoma: overview of histopathologic characteristics and molecular genetic findings. J. Hepatobiliary Pancreatic. Surg. 2000; 7: 556-567
5. Roa I., Araya J.C., Villaseca M., et al. Preneoplastic lesions in gallbladder cancer: an estimate of the period required for progression. Gastroenterol. 1996; 111: 232-236
6. Mohan S., Epstein J.B. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 2003; 39: 537-546.
7. Tomozawa S., Tsuno N.H., Sunami E., et al. Cycooxygenase-2 overexpression correlates with tumor recurrence, especially hae-matogenous metastasis, of colorectal cancer. Br. J. Cancer 2000; 83: 324-328
8. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R. Host cyclo-oxygenase-2 modulates carcinoma growth. J. Clin. Invest. 2000; 105:1589-1594.
9. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends in Pharmacol. Sci. 2003; 24:96-102.
10. Asano T., ShodaJ., Ueda T., et al. Expression of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crusial role of arachinodate metabolism in tumor growth and progression. Clin. Cancer Res. 2002; 8:1157-1167.
11. Legan M., Luzar B., Marolt V.F., Cör A. Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant lesions. World J. Gastroenterol. 2006; 12: 3425-3429.
12. Fumino S., Tokiwa K., Ono S., Iwai N. Cyclooxygenase-2 expression in the gallbladder of patients with anomalous arrangement of pancreaticobiliary duct. J. Pediat. Surg. 2003; 38: 585-589.
13. Kawamoto T., Shoda J., Asano T., et al. Expression of cycloooxy-genase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int. J. Cancer 2002; 89:427-434.
14. Honjo S., Kase S., Osaki M., Ardyanto T.D., Kaibara N., Ito H. Cyclooxygenase-2 expression in human gastric tubular adenomas and carcinomas: correlation with intratumoral microvessel density and apoptotic index. Anticancer Res. 2004; 24:1439-1444.
15. Lane D.P. Cancer. P53, guardian of the genome. Nature 1992; 358: 15-16
16. Levine A.J. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-231
17. Da Rocha A.O., Coutinho L.M.B., Scholl J.G., Leboutte L.D.P. The value of p53 protein expression in gallbladder carcinoma: analysis of 60 cases. Hepato-Gastroenterol. 2004; 51:1310-1314.
18. Wee A., Teh M., Raju G.C. Clinical importance of ps3 protein in gall bladder carcinoma and its precursor lesions. J. Clin. Pathol. 1994; 47:453-456.
19. Sessa F., Furlan D., Genasetti A., Billo P., Feltri M., Capella C. Mi-crosatellite instability and p53 expression in gallbladder carcinomas. Diagn. Molecul. Pathol. 2003; 12:96-102.
20. Corcoran C.A., He Q., Huang Y., Sheikh M.S. Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene 2005; 24:1634-1640.
21. Swamy M.V., Herzog C.R., Rao C.V. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res. 2003; 63: 5239-5242.
22. Steinbach G., Lynch P.M., Phillips R.K.S., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. NewEngl. J. Med. 2000; 342:1946-1952.
23. Harris R.E. Cyclooxygenase-2 (COX-2) blockade in the chemo-prevention of cancers of the colon, breast, prostatem and lung. Inflammopharmacol. 2009; 17: 55-67.
24. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular vents taking low-dose aspirin? Lancet 2007; 370: 2138-2151.
25. Dills W.L. Nutritional and physiological consequences of tumour glycolysis. Parasitol.1993; 107: S177-1786.
26. Ebert B.L., Firth J.D., Ratcliffe P.J. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J. Biol. Chem. 1995; 270: 29083-29089.
27. Airley R., Loncaster J., Davidson S., et al. Glucose transporter Glut-i expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. Cancer Res. 2001; 7:928-934.
28. Amann T., Maegdefrau U., Hartmann A., et al. GLUTi expression is increased in hepatocellular carcinoma and promotes tu-morigenesis. Am. J. Pathol. 2009; 174:1544-1552.
29. Younes M., Lechago L.V., Somoano J.R., MosharafM., Lechago J. Wide expression of the human erythrocyte glucose transporter Glut-1 in human cancers. Cancer Res. 1996; 56:1164-1167.
30. Kim Y.W., Park Y.K., Yoon T., Lee S.M. Expression of GLUT-1 glucose transporter in gallbladder carcinomas. Hepato-Gastroen-terol. 2002; 49:907-911.
31. Legan M., Tevžič Š., Tolar A., Luzar B., Marolt V.F. Glucose transporter-1 (GLUT-1) immunoreactivity in benign, premalig-nant and malignant lesions of the gallbladder. Pathol.Oncol. Res. 2010 May 29 [Epub ahead of print].
32. Griffiths E.A., Pritchard S.A., Welch I.M., et al. Is the hypoxia-in-ducible factor Pathway important in gastric cancer? Eur. J. Cancer 2005; 41: 2792-2805.
33. Legan M., Luzar B., Marolt V.F. Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinoma and their impact on prognosis. Scand. J.Gastroenterol. 2009; 44: 1101-1108